Developer docs
API playgroundTry for free, no card

Search company profiles

Xenopat

Full company profile

uuid000fu57

Namestring
Xenopat
Legal namestring
Xenopat S.L.
Websiteurl
xenopat.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Xenopat S.L. is a Spanish preclinical oncology services company operating as a spin-off of the Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), and Bellvitge University Hospital (HUB), headquartered in L'Hospitalet de Llobregat, Barcelona. The company specializes in orthotopic Patient-Derived Xenograft (PDX) models branded as "orthoxenografts®," in which a small fragment of a human tumor is implanted in the corresponding organ of immunodeficient mice within 24 hours of surgical removal. These models preserve the histological, genetic, and molecular characteristics of the original tumor and are the basis for two service lines: Advanced Preclinical Services sold to pharmaceutical and biotech clients (including drug response evaluation, MTD studies, co-clinical trials, drug repositioning, and acquired resistance studies) and Personalized Cancer Treatment delivered through oncologists and the Bellvitge hospital network (producing patient-specific drug response reports known as the "antiquimiograma" within 4–8 months). The core technology asset is the OrthoXenoBank®, a proprietary collection of more than 350 characterized orthotopic PDX models spanning colon, lung, breast, ovarian, pancreatic, endometrial, head and neck, liver, and germ cell tumors, including matched chemotherapy-sensitive and resistant pairs.

The company is privately held, organized as a Sociedad Limitada (C.I.F. B66362088), founded in 2014, and operates with 1–10 employees. Revenue is generated through project-based professional services contracts with pharmaceutical companies and direct payments from patients for personalized treatment, with no publicly disclosed pricing; a small prefixed implantation fee applies if a tumor fails to engraft (typical engraftment rates 70–75%). The firm does not operate any self-serve or e-commerce channel, instead relying on direct sales engagement and clinical collaboration through its hospital partner network. Go-to-market is supplemented by an active portfolio of EU-funded research consortia (Horizon 2020, IMI2, Eurostars, MSCA, AGAUR, Doctorados Industriales) that provide non-dilutive funding, scientific credibility, and partner visibility across European oncology research. Xenopat is led by three co-founders: CEO Anna Portela (PhD in Genetics, ESADE MBA), CSO Alberto Villanueva (inventor of the orthoxenograft terminology, 60+ publications), and Chief of Molecular Pathology August Vidal (70+ publications, pathologist at HUB).

Short descriptiontext

Xenopat S.L. is a Barcelona-based preclinical oncology services company providing orthotopic Patient-Derived Xenograft (PDX) models (orthoxenografts®) and a 350+ model OrthoXenoBank® to pharmaceutical companies for anticancer drug development and to oncologists and patients for personalized cancer treatment guidance, operating as a spin-off of ICO, IDIBELL, and Bellvitge University Hospital.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersL'hospitalet De Llobregat, Spain
HQ citystring
L'hospitalet De Llobregat
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical oncology services, patient-derived xenografts, orthotopic tumor models, anticancer drug development, personalized cancer treatment
Industry3 codes
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAC
Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Medical Laboratories621511
  • Other Ambulatory Health Care Services6219
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Oncology Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Advanced Preclinical Services
TypeProfessional Services
Description

Contract research services offered to pharmaceutical companies and researchers developing new anticancer drugs. Services include: generation of customized cell lines, Maximum Tolerated Dose determination, dosage schedule studies, drug combination optimization, drug response evaluation using clinicopathological standards, gene expression analysis, genetic/epigenetic studies, identification of drug targets/mechanisms of action, generation of customized orthoxenografts, co-clinical paired trials in human and mice, drug repositioning studies, and acquired resistance studies. Revenue is earned through project-based service contracts, likely billed per study or milestone.

xenopat.com
2Personalized Cancer Treatment
TypeProfessional Services
Description

Direct-to-patient service generating patient-specific orthoxenografts for personalized oncology treatment guidance. The process produces an antiquimiograma (Response Report) recommending optimal therapy. Patients pay for the service, with the process taking 4–8 months from tumor implantation to report delivery. Cryopreservation services for future reimplantation are also offered.

xenopat.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 3 records shown
1OrthoXenoBank
Description

Collection of orthoxenograft models (orthotopic patient-derived xenografts) for preclinical oncology drug research, comprising over 350 models across multiple tumor types.

xenopat.com
+2 more records
Core offering1 text field

Xenopat provides preclinical oncology contract research services and personalized cancer treatment guidance built on its proprietary orthotopic Patient-Derived Xenograft (orthoxenograft®) models. Its two main commercial offerings are Advanced Preclinical Services — drug response evaluation, MTD determination, drug combination optimization, gene expression and genetic/epigenetic studies, co-clinical trials, drug repositioning, and acquired resistance studies — sold to pharmaceutical and biotech clients, and Personalized Cancer Treatment — generation of patient-specific orthoxenografts and an Antiquimiograma (Response Report) — sold to oncologists and patients in collaboration with hospital partners. The OrthoXenoBank® of more than 350 characterized orthotopic PDX models is the underlying asset for both lines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Engraftment rates of 70–75% depending on tumor type and fragment size
+2 more records
Product overview1 text field

Xenopat is a preclinical oncology services company offering two main service areas: Advanced Preclinical Services for drug development researchers and pharmaceutical companies, and Personalized Cancer Treatment for healthcare professionals and patients. The core product is OrthoXenoBank®, a collection of more than 350 orthoxenograft models (orthotopic patient-derived xenografts/PDXs), which are mouse models implanting human tumor fragments in their matching organ of origin. These orthoxenografts maintain histological and genetic characteristics of original tumors and mimic drug response patterns. Services include customized orthoxenograft generation, drug response evaluation, genetic/epigenetic studies, and co-clinical trials. For personalized treatment, the company generates patient-specific orthoxenografts to test drug alternatives and delivers a Response Report (antiquimiograma) guiding treatment selection.

Product and service5 records
1Advanced Preclinical Services
CategoryPreclinical Oncology Contract Research
Description

Contract research partnership offering pharmaceutical companies, biotech firms, and academic researchers the most innovative tools for oncological drug development, including access to the OrthoXenoBank®, customized orthoxenograft generation, drug response evaluation, Maximum Tolerated Dose determination, drug combination optimization, dosage schedule studies, gene expression analysis, genetic and epigenetic studies, identification of drug targets/mechanisms of action, co-clinical paired trials in mice and humans, drug repositioning studies, and acquired resistance studies.

2Personalized Cancer Treatment
CategoryPersonalized Oncology Services
Description

Healthcare service that generates orthoxenografts from a small fragment of a patient's tumor, tests multiple drugs on colony subpopulations, and produces an Antiquimiograma (Response Report) recommending the most appropriate therapy. Delivered to oncologists and patients (particularly those with aggressive, refractory, or relapsing tumors) in coordination with hospital partners such as Bellvitge University Hospital, with optional cryopreservation for future reimplantation in case of relapse.

3OrthoXenoBank®
CategoryPreclinical Oncology Model Bank
Description

A collection of more than 350 orthotopic PDX models (orthoxenografts®) representing the most frequent histological subtypes of tumors in colon, lungs, breasts, ovaries, pancreas, endometrium, head and neck, liver, and germ cells. All models are classified by histological subtype and genetically characterized for the most relevant mutations, with some carrying acquired resistance to standard chemotherapy and others being endogenous refractory tumors; the bank also contains matched chemotherapy-sensitive and -resistant orthoxenograft pairs generated through repeated treatment exposure in vivo. Licensed/provided to pharmaceutical and biotech clients as part of Advanced Preclinical Services engagements.

4Orthoxenografts®
CategoryPreclinical Oncology Model Generation
Description

Mouse models in which a small piece of human tumor is implanted orthotopically in the same organ of origin (also known as Patient-Derived Orthotopic Xenografts, PDXs/PDOXs). Xenopat develops and supplies these models to maintain the histological, genetic, and molecular characteristics of the original tumor and to mimic drug response patterns, including generation of customized orthoxenografts for specific client projects.

5In Vitro Pre-Screening Platform
CategoryIn Vitro Preclinical Drug Screening
Description

Preclinical drug-screening service in development that establishes cell lines derived from patient-derived xenografts (PDXs) for in vitro drug testing, designed to enhance the efficiency of preclinical oncology drug research, reduce animal use, and maintain the predictive power of PDX models in line with the 3Rs principle and recent regulatory changes.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

EU Horizon-funded MSCA Staff Exchanges 2023 project (Jan 2025–Dec 2028) focused on standardizing extracellular vesicle isolation and characterization for biomarkers and drug delivery vehicles. Xenopat is a consortium member alongside 8+ institutions.

2In Vitro Pre-Screening Platform (Doctorados Industriales, Ministerio de Ciencia)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Spanish Ministry of Science funded doctoral industrial project (Oct 2024–Oct 2028) developing an in vitro pre-screening service using PDX-derived cell lines to reduce animal use in preclinical oncology while maintaining predictive power.

xenopat.com
3In Vitro PDX Cell Lines (Doctorat Industrial AGAUR)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Catalan AGAUR-funded doctoral industrial project (Oct 2024–Oct 2027) establishing cell lines from patient-derived xenografts for in vitro drug screening, reducing animal use in line with the 3Rs principle.

xenopat.com
4GlioPep (Eurostars-Eureka, CDTI)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-03-01
Description

Eurostars-Eureka funded project (Mar 2023–Mar 2026) developing a next-generation peptide drug conjugate as a novel tumor-specific treatment for glioblastoma. Co-funded by EU HorizonEurope and CDTI.

xenopat.com
5DEFIT-CRC (Tecniospring, ACCIÓ)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-03-01
Description

ACCIÓ Tecniospring talent program project (Mar 2022–Oct 2024) developing a T14 inhibitor for treatment of colorectal cancer, hiring qualified R&D personnel.

xenopat.com
6PERSIST-SEQ (Innovative Medicines Initiative 2)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-07-01
Description

IMI2 and EFPIA-funded project (Jul 2021–Jun 2026) developing a standardized single-cell workflow to study cancer treatment resistance, characterizing 5 million cells in lung, colorectal, and breast cancer models.

xenopat.com
7ColoSelect (Eurostars-2, CDTI)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

Eurostars-2 funded project (Apr 2021–Jan 2024) developing BOT1700, a theranostic nanobody targeting PDGF-beta receptor for PET imaging and targeted radiotherapy in CMS4 colorectal cancer.

xenopat.com
8CRYSTAL3 (EU Horizon 2020 MSCA RISE)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

EU Horizon 2020 MSCA RISE consortium (Jan 2021–Dec 2024) with 12 members in 8 countries, led by University College Dublin, investigating cysteinyl leukotriene signaling in cancer and cardiovascular disease. €887,800 funding.

xenopat.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-10-01
Description

Eurostars-funded project (Oct 2019–Oct 2022) developing a first-in-class monoclonal antibody therapy targeting a novel tumor-specific epitope for ovarian cancer treatment.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-02-01
Description

ERC Proof of Concept Grant (Feb 2017–Jul 2018) developing a DNA methylation kit targeting non-coding RNA regions to support treatment decisions in Cancer of Unknown Primary (CUP).

113D NEONET (EU Research Consortium)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

EU research consortium (Jan 2017–Jun 2022) bringing together 18 institutions in 7 countries to accelerate therapeutic development for oncology and ophthalmology.

xenopat.com
12Catalan Institute of Oncology (ICO)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Xenopat is a spin-off company of the Catalan Institute of Oncology (ICO). The Drug Resistance Group at ICO-IDIBELL, led by co-founder Alberto Villanueva, serves as the principal investigator group, providing institutional research backing and access to clinical specimens.

xenopat.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Xenopat is a spin-off of the Bellvitge Biomedical Research Institute (IDIBELL). The institute provides research infrastructure, talent, and clinical collaboration for Xenopat's orthoxenograft development activities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Xenopat is a spin-off of the Bellvitge University Hospital (HUB). Co-founder August Vidal is a pathologist at HUB. The hospital provides clinical specimens and pathology expertise essential for orthoxenograft characterization.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Provider of genetically engineered mouse models and related preclinical services with growing oncology and PDX offerings. Comparable but broader in mouse model portfolio than Xenopat's orthotopic specialty.

TypeDirect peer
Description

French preclinical CRO specializing in oncology drug discovery and translational models, including patient-derived xenografts and pharmacological profiling. Comparable European peer with similar pharma customer base and service mix.

TypeEmerging player
Description

Precision oncology company offering molecular profiling and AI-driven treatment recommendations for cancer patients. Adjacent competitor in personalized oncology treatment selection, though using molecular rather than in vivo functional testing.

TypeDirect peer
Description

US-based oncology CRO specializing in patient-derived xenograft (PDX) models, tumor organoids, and personalized oncology services. Directly competes with Xenopat in offering PDX-based preclinical and translational services to pharma and patients.

5Tempus
TypeEmerging player
Description

AI-driven precision medicine company providing molecular profiling, multi-omic data, and treatment decision support for oncology. Adjacent player in evidence-based personalized oncology treatment guidance.

TypeBroad incumbent
Description

Large nonprofit biomedical research institution providing PDX model development, mouse model distribution, and preclinical oncology services. Broader incumbent with overlapping translational model capabilities but much wider scope.

TypeBroad incumbent
Description

Large global CRO with significant oncology preclinical services including PDX and tumor model offerings. Broad incumbent whose oncology segment overlaps with Xenopat's pharma services.

8Experimental Pharmacology and Oncology (EPO)
TypeDirect peer
Description

German-based preclinical oncology CRO offering PDX models, patient-derived tumor models, and in vivo pharmacology services to pharma clients. Comparable specialty European CRO in the same niche.

TypeDirect peer
Description

Global preclinical and translational CRO with one of the largest collections of PDX models (HuPrime®) and oncology drug development services. Closest large-scale direct competitor to Xenopat's OrthoXenoBank® offering.

TypeDirect peer
Description

French preclinical CRO focused on oncology and immuno-oncology using patient-derived tumor models, including PDX and ex vivo approaches. Comparable specialty CRO serving pharma clients with translational oncology services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xenopat

Preclinical Oncology Research Servicesxenopat.com

Xenopat S.L. is a Barcelona-based preclinical oncology services company providing orthotopic Patient-Derived Xenograft (PDX) models (orthoxenografts®) and a 350+ model OrthoXenoBank® to pharmaceutical companies for anticancer drug development and to oncologists and patients for personalized cancer treatment guidance, operating as a spin-off of ICO, IDIBELL, and Bellvitge University Hospital.

What Xenopat does

Xenopat S.L. is a Spanish preclinical oncology services company operating as a spin-off of the Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), and Bellvitge University Hospital (HUB), headquartered in L'Hospitalet de Llobregat, Barcelona. The company specializes in orthotopic Patient-Derived Xenograft (PDX) models branded as "orthoxenografts®," in which a small fragment of a human tumor is implanted in the corresponding organ of immunodeficient mice within 24 hours of surgical removal. These models preserve the histological, genetic, and molecular characteristics of the original tumor and are the basis for two service lines: Advanced Preclinical Services sold to pharmaceutical and biotech clients (including drug response evaluation, MTD studies, co-clinical trials, drug repositioning, and acquired resistance studies) and Personalized Cancer Treatment delivered through oncologists and the Bellvitge hospital network (producing patient-specific drug response reports known as the "antiquimiograma" within 4–8 months). The core technology asset is the OrthoXenoBank®, a proprietary collection of more than 350 characterized orthotopic PDX models spanning colon, lung, breast, ovarian, pancreatic, endometrial, head and neck, liver, and germ cell tumors, including matched chemotherapy-sensitive and resistant pairs.

The company is privately held, organized as a Sociedad Limitada (C.I.F. B66362088), founded in 2014, and operates with 1–10 employees. Revenue is generated through project-based professional services contracts with pharmaceutical companies and direct payments from patients for personalized treatment, with no publicly disclosed pricing; a small prefixed implantation fee applies if a tumor fails to engraft (typical engraftment rates 70–75%). The firm does not operate any self-serve or e-commerce channel, instead relying on direct sales engagement and clinical collaboration through its hospital partner network. Go-to-market is supplemented by an active portfolio of EU-funded research consortia (Horizon 2020, IMI2, Eurostars, MSCA, AGAUR, Doctorados Industriales) that provide non-dilutive funding, scientific credibility, and partner visibility across European oncology research. Xenopat is led by three co-founders: CEO Anna Portela (PhD in Genetics, ESADE MBA), CSO Alberto Villanueva (inventor of the orthoxenograft terminology, 60+ publications), and Chief of Molecular Pathology August Vidal (70+ publications, pathologist at HUB).

Xenopat firmographics

Firmographics
Name
Xenopat
Legal name
Xenopat S.L.
Website
https://xenopat.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Xenopat S.L. is a Barcelona-based preclinical oncology services company providing orthotopic Patient-Derived Xenograft (PDX) models (orthoxenografts®) and a 350+ model OrthoXenoBank® to pharmaceutical companies for anticancer drug development and to oncologists and patients for personalized cancer treatment guidance, operating as a spin-off of ICO, IDIBELL, and Bellvitge University Hospital.
Ownership category
akta.pro rank

Xenopat industry classification

Industry
Product category
Preclinical Oncology Research Services
NAICS
Medical Laboratories (621511), Other Ambulatory Health Care Services (6219)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAC
Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Preclinical oncology services
  • Patient-derived xenografts
  • Orthotopic tumor models
  • Anticancer drug development
  • Personalized cancer treatment

Where Xenopat is headquartered

Location

Headquarters

HQ city
L'hospitalet De Llobregat
HQ country
Spain
HQ region
Europe

Offices1 record

Markets served

Xenopat business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

  1. Advanced Preclinical Services: Contract research services offered to pharmaceutical companies and researchers developing new anticancer drugs. Services include: generation of customized cell lines, Maximum Tolerated Dose determination, dosage schedule studies, drug combination optimization, drug response evaluation using clinicopathological standards, gene expression analysis, genetic/epigenetic studies, identification of drug targets/mechanisms of action, generation of customized orthoxenografts, co-clinical paired trials in human and mice, drug repositioning studies, and acquired resistance studies. Revenue is earned through project-based service contracts, likely billed per study or milestone.
  2. Personalized Cancer Treatment: Direct-to-patient service generating patient-specific orthoxenografts for personalized oncology treatment guidance. The process produces an antiquimiograma (Response Report) recommending optimal therapy. Patients pay for the service, with the process taking 4–8 months from tumor implantation to report delivery. Cryopreservation services for future reimplantation are also offered.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Xenopat product offering

Product offering

Core offering

Xenopat provides preclinical oncology contract research services and personalized cancer treatment guidance built on its proprietary orthotopic Patient-Derived Xenograft (orthoxenograft®) models. Its two main commercial offerings are Advanced Preclinical Services — drug response evaluation, MTD determination, drug combination optimization, gene expression and genetic/epigenetic studies, co-clinical trials, drug repositioning, and acquired resistance studies — sold to pharmaceutical and biotech clients, and Personalized Cancer Treatment — generation of patient-specific orthoxenografts and an Antiquimiograma (Response Report) — sold to oncologists and patients in collaboration with hospital partners. The OrthoXenoBank® of more than 350 characterized orthotopic PDX models is the underlying asset for both lines.

Product overview

Xenopat is a preclinical oncology services company offering two main service areas: Advanced Preclinical Services for drug development researchers and pharmaceutical companies, and Personalized Cancer Treatment for healthcare professionals and patients. The core product is OrthoXenoBank®, a collection of more than 350 orthoxenograft models (orthotopic patient-derived xenografts/PDXs), which are mouse models implanting human tumor fragments in their matching organ of origin. These orthoxenografts maintain histological and genetic characteristics of original tumors and mimic drug response patterns. Services include customized orthoxenograft generation, drug response evaluation, genetic/epigenetic studies, and co-clinical trials. For personalized treatment, the company generates patient-specific orthoxenografts to test drug alternatives and delivers a Response Report (antiquimiograma) guiding treatment selection.

Differentiator

Problem solved

Functional benefit

Brands

  • OrthoXenoBank: Collection of orthoxenograft models (orthotopic patient-derived xenografts) for preclinical oncology drug research, comprising over 350 models across multiple tumor types.
  • Orthoxenografts
  • Antiquimiograma

Products and services

  • Advanced Preclinical Services Contract research partnership offering pharmaceutical companies, biotech firms, and academic researchers the most innovative tools for oncological drug development, including access to the OrthoXenoBank®, customized orthoxenograft generation, drug response evaluation, Maximum Tolerated Dose determination, drug combination optimization, dosage schedule studies, gene expression analysis, genetic and epigenetic studies, identification of drug targets/mechanisms of action, co-clinical paired trials in mice and humans, drug repositioning studies, and acquired resistance studies.
  • Personalized Cancer Treatment Healthcare service that generates orthoxenografts from a small fragment of a patient's tumor, tests multiple drugs on colony subpopulations, and produces an Antiquimiograma (Response Report) recommending the most appropriate therapy. Delivered to oncologists and patients (particularly those with aggressive, refractory, or relapsing tumors) in coordination with hospital partners such as Bellvitge University Hospital, with optional cryopreservation for future reimplantation in case of relapse.
  • OrthoXenoBank® A collection of more than 350 orthotopic PDX models (orthoxenografts®) representing the most frequent histological subtypes of tumors in colon, lungs, breasts, ovaries, pancreas, endometrium, head and neck, liver, and germ cells. All models are classified by histological subtype and genetically characterized for the most relevant mutations, with some carrying acquired resistance to standard chemotherapy and others being endogenous refractory tumors; the bank also contains matched chemotherapy-sensitive and -resistant orthoxenograft pairs generated through repeated treatment exposure in vivo. Licensed/provided to pharmaceutical and biotech clients as part of Advanced Preclinical Services engagements.
  • Orthoxenografts® Mouse models in which a small piece of human tumor is implanted orthotopically in the same organ of origin (also known as Patient-Derived Orthotopic Xenografts, PDXs/PDOXs). Xenopat develops and supplies these models to maintain the histological, genetic, and molecular characteristics of the original tumor and to mimic drug response patterns, including generation of customized orthoxenografts for specific client projects.
  • In Vitro Pre-Screening Platform Preclinical drug-screening service in development that establishes cell lines derived from patient-derived xenografts (PDXs) for in vitro drug testing, designed to enhance the efficiency of preclinical oncology drug research, reduce animal use, and maintain the predictive power of PDX models in line with the 3Rs principle and recent regulatory changes.

Quantifiable outcome

  • Engraftment rates of 70–75% depending on tumor type and fragment size
  • +2 more outcomes

Companies that use Xenopat

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Xenopat technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Xenopat partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered minor and core.

  • EVEREST (Extracellular Vesicle Research Exchanges for Advanced Biomarkers and Therapeutics)minorStrategic or Co-development Partner · 1 January 2025EU Horizon-funded MSCA Staff Exchanges 2023 project (Jan 2025–Dec 2028) focused on standardizing extracellular vesicle isolation and characterization for biomarkers and drug delivery vehicles. Xenopat is a consortium member alongside 8+ institutions.
  • In Vitro Pre-Screening Platform (Doctorados Industriales, Ministerio de Ciencia)minorStrategic or Co-development Partner · 1 October 2024Spanish Ministry of Science funded doctoral industrial project (Oct 2024–Oct 2028) developing an in vitro pre-screening service using PDX-derived cell lines to reduce animal use in preclinical oncology while maintaining predictive power.
  • In Vitro PDX Cell Lines (Doctorat Industrial AGAUR)minorStrategic or Co-development Partner · 1 October 2024Catalan AGAUR-funded doctoral industrial project (Oct 2024–Oct 2027) establishing cell lines from patient-derived xenografts for in vitro drug screening, reducing animal use in line with the 3Rs principle.
  • GlioPep (Eurostars-Eureka, CDTI)minorStrategic or Co-development Partner · 1 March 2023Eurostars-Eureka funded project (Mar 2023–Mar 2026) developing a next-generation peptide drug conjugate as a novel tumor-specific treatment for glioblastoma. Co-funded by EU HorizonEurope and CDTI.
  • DEFIT-CRC (Tecniospring, ACCIÓ)minorStrategic or Co-development Partner · 1 March 2022ACCIÓ Tecniospring talent program project (Mar 2022–Oct 2024) developing a T14 inhibitor for treatment of colorectal cancer, hiring qualified R&D personnel.
  • PERSIST-SEQ (Innovative Medicines Initiative 2)minorStrategic or Co-development Partner · 1 July 2021IMI2 and EFPIA-funded project (Jul 2021–Jun 2026) developing a standardized single-cell workflow to study cancer treatment resistance, characterizing 5 million cells in lung, colorectal, and breast cancer models.
  • ColoSelect (Eurostars-2, CDTI)minorStrategic or Co-development Partner · 1 April 2021Eurostars-2 funded project (Apr 2021–Jan 2024) developing BOT1700, a theranostic nanobody targeting PDGF-beta receptor for PET imaging and targeted radiotherapy in CMS4 colorectal cancer.
  • CRYSTAL3 (EU Horizon 2020 MSCA RISE)minorStrategic or Co-development Partner · 1 January 2021EU Horizon 2020 MSCA RISE consortium (Jan 2021–Dec 2024) with 12 members in 8 countries, led by University College Dublin, investigating cysteinyl leukotriene signaling in cancer and cardiovascular disease. €887,800 funding.
  • nOVAB (Eurostars)minorStrategic or Co-development Partner · 1 October 2019Eurostars-funded project (Oct 2019–Oct 2022) developing a first-in-class monoclonal antibody therapy targeting a novel tumor-specific epitope for ovarian cancer treatment.
  • EpiPharm (European Research Council Proof of Concept)minorStrategic or Co-development Partner · 1 February 2017ERC Proof of Concept Grant (Feb 2017–Jul 2018) developing a DNA methylation kit targeting non-coding RNA regions to support treatment decisions in Cancer of Unknown Primary (CUP).
  • 3D NEONET (EU Research Consortium)minorStrategic or Co-development Partner · 1 January 2017EU research consortium (Jan 2017–Jun 2022) bringing together 18 institutions in 7 countries to accelerate therapeutic development for oncology and ophthalmology.
  • Catalan Institute of Oncology (ICO)coreStrategic or Co-development PartnerXenopat is a spin-off company of the Catalan Institute of Oncology (ICO). The Drug Resistance Group at ICO-IDIBELL, led by co-founder Alberto Villanueva, serves as the principal investigator group, providing institutional research backing and access to clinical specimens.
  • Bellvitge Biomedical Research Institute (IDIBELL)coreStrategic or Co-development PartnerXenopat is a spin-off of the Bellvitge Biomedical Research Institute (IDIBELL). The institute provides research infrastructure, talent, and clinical collaboration for Xenopat's orthoxenograft development activities.
  • Bellvitge University Hospital (HUB)coreStrategic or Co-development PartnerXenopat is a spin-off of the Bellvitge University Hospital (HUB). Co-founder August Vidal is a pathologist at HUB. The hospital provides clinical specimens and pathology expertise essential for orthoxenograft characterization.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Xenopat competitors and assessment

Company assessment

Emerging players

  • Taconic Biosciences: Provider of genetically engineered mouse models and related preclinical services with growing oncology and PDX offerings. Comparable but broader in mouse model portfolio than Xenopat's orthotopic specialty.
  • Caris Life Sciences: Precision oncology company offering molecular profiling and AI-driven treatment recommendations for cancer patients. Adjacent competitor in personalized oncology treatment selection, though using molecular rather than in vivo functional testing.
  • Tempus: AI-driven precision medicine company providing molecular profiling, multi-omic data, and treatment decision support for oncology. Adjacent player in evidence-based personalized oncology treatment guidance.

Direct peers

  • Oncodesign: French preclinical CRO specializing in oncology drug discovery and translational models, including patient-derived xenografts and pharmacological profiling. Comparable European peer with similar pharma customer base and service mix.
  • Champions Oncology: US-based oncology CRO specializing in patient-derived xenograft (PDX) models, tumor organoids, and personalized oncology services. Directly competes with Xenopat in offering PDX-based preclinical and translational services to pharma and patients.
  • Experimental Pharmacology and Oncology (EPO): German-based preclinical oncology CRO offering PDX models, patient-derived tumor models, and in vivo pharmacology services to pharma clients. Comparable specialty European CRO in the same niche.
  • Crown Bioscience: Global preclinical and translational CRO with one of the largest collections of PDX models (HuPrime®) and oncology drug development services. Closest large-scale direct competitor to Xenopat's OrthoXenoBank® offering.
  • Xentech: French preclinical CRO focused on oncology and immuno-oncology using patient-derived tumor models, including PDX and ex vivo approaches. Comparable specialty CRO serving pharma clients with translational oncology services.

Broad incumbents

  • The Jackson Laboratory: Large nonprofit biomedical research institution providing PDX model development, mouse model distribution, and preclinical oncology services. Broader incumbent with overlapping translational model capabilities but much wider scope.
  • Charles River Laboratories: Large global CRO with significant oncology preclinical services including PDX and tumor model offerings. Broad incumbent whose oncology segment overlaps with Xenopat's pharma services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Xenopat social profiles

Digital presence

Xenopat financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xenopat leadership team

Management profile

Number of profiles

Profiles3 records

Xenopat funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xenopat M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xenopat

What does Xenopat do?

Xenopat provides preclinical oncology contract research services and personalized cancer treatment guidance built on its proprietary orthotopic Patient-Derived Xenograft (orthoxenograft®) models. Its two main commercial offerings are Advanced Preclinical Services — drug response evaluation, MTD determination, drug combination optimization, gene expression and genetic/epigenetic studies, co-clinical trials, drug repositioning, and acquired resistance studies — sold to pharmaceutical and biotech clients, and Personalized Cancer Treatment — generation of patient-specific orthoxenografts and an Antiquimiograma (Response Report) — sold to oncologists and patients in collaboration with hospital partners. The OrthoXenoBank® of more than 350 characterized orthotopic PDX models is the underlying asset for both lines.

Is Xenopat a public or private company?

Xenopat is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Xenopat founded?

Xenopat was founded in 2014. It employs 1 to 10 people.

Where is Xenopat based?

Xenopat is headquartered in L'hospitalet De Llobregat, Spain, in the Europe region.

How does Xenopat make money?

Two revenue lines are on record. Advanced Preclinical Services are the primary driver. The others are personalized Cancer Treatment.

Who are Xenopat's main competitors?

Emerging players on record are Taconic Biosciences, Caris Life Sciences and Tempus. Direct peers are Oncodesign, Champions Oncology, Experimental Pharmacology and Oncology (EPO), Crown Bioscience and Xentech. Broad incumbents are The Jackson Laboratory and Charles River Laboratories.

Does Xenopat have an API?

No public API is recorded for Xenopat.

What industry is Xenopat in?

Xenopat's product category is Preclinical Oncology Research Services. Its primary akta.pro industry code is HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy), with a secondary code of HLAIALAC, Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology). Its NAICS code is 621511 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals